APA (7th ed.) Citation

K, Y., RS, T., TK, B., RA, S., M, K., J, C., . . . P, M. (2026). Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(10), 1946. https://doi.org/10.1158/1078-0432.CCR-25-4518

Chicago Style (17th ed.) Citation

K, Yu, et al. "Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 32, no. 10 (2026): 1946. https://doi.org/10.1158/1078-0432.CCR-25-4518.

MLA (9th ed.) Citation

K, Yu, et al. "Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 32, no. 10, 2026, p. 1946, https://doi.org/10.1158/1078-0432.CCR-25-4518.